#2924
Everolimus in Patients with Advanced Neuroendocrine Neoplasia: A Real-World Study and Analysis of Long Responders
Introduction:
Everolimus is a valid therapeutic option for neuroendocrine tumors (NETs); however, data regarding the long responsders in a real-world setting, outside regulatory trials, are scanty.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Rinzivillo M
Authors:
Rinzivillo M,
De Felice I,
Magi L,
Prosperi D,
Iannicelli E,
Keywords:
everolimus,
neuroendocrine neoplasia,
progressive disease,
target therapy,
#2819
Occurrence of Pancreatic Exocrine Insufficiency in Patients with Advanced Neuroendocrine Tumours Treated with Somatostatin Analogue
Introduction:
Neuroendocrine neoplasia (NENs) are heterogeneous tumours caracterized by a relatively indolent rate of growth. Usually, in G1 and G2 GEP-NENs, first-line therapy is SSAs, considering their efficacy, good safety profile, and antiproliferative effects. SSA treatment inhibits the production and excretion of pancreatic enzymes and PEI is known to be an adverse effect of SSA treatment.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Rinzivillo M
Authors:
De Felice I,
Rinzivillo M,
Pratesi M,
Magi L,
Annibale B,
Keywords:
Pancreatic Exocrine Insufficiency,
